Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | AGXT | P21549 | 2/20 | 0.36 |
| ▸ | REN | P00797 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3506973 | 0.87 | OPRM1 (0.38) | CARM1PRMT6HRH3 | |
| SCHEMBL14899262 | 0.77 | — | — | |
| SCHEMBL10692174 | 0.74 | OPRM1 (0.41) | CARM1PRMT6HRH3 | |
| SCHEMBL15007794 | 0.73 | IDO1 (0.37) | NAAAIDO1AGXTRENKDM4E | |
| SCHEMBL15007796 | 0.73 | IDO1 (0.37) | NAAAIDO1AGXTRENKDM4E | |
| SCHEMBL18287587 | 0.73 | NAAA (0.37) | NAAAIDO1AGXTKDM4EMAPT | |
| SCHEMBL6968463 | 0.72 | OPRM1 (0.43) | NAAACARM1PRMT6HRH3 | |
| SCHEMBL2407150 | 0.70 | PREP (0.36) | NAAAIDO1AGXTRENKDM4E | |
| SCHEMBL15032442 | 0.69 | NAAA (0.38) | NAAAIDO1AGXTRENKDM4E | |
| SCHEMBL16654046 | 0.68 | NAAA (0.54) | NAAAIDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150314-A1 | TRIOXACARCINS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150314-A1 | TRIOXACARCINS AND USES THEREOF | PCSK9, PCSK7, ABCC9 | NAAA 1790/4885IDO1 3700/4885AGXT 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.